Public health implications of legalising the production and sale of cannabis for medicinal and recreational use

The Lancet

Volumn 394, Issue 10208, 2019, Pages 1580-1590

  Hall, Wayne ^a,b   Stjepanović, Daniel ^a   Caulkins, Jonathan ^c   Lynskey, Michael ^b   Leung, Janni ^a,d   Campbell, Gabrielle ^d   Degenhardt, Louisa ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; MEDICAL CANNABIS;

ALCOHOL CONSUMPTION; CANADA; CLINICAL EVALUATION; DRUG EFFECT; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; LEGAL ASPECT; MARKETING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RECREATIONAL THERAPY; REVIEW; TOBACCO USE; UNITED STATES; URUGUAY; ADVERSE EVENT; CANNABIS USE; COMMERCIAL PHENOMENA; DRUG DEPENDENCE; DRUG LEGISLATION; ECONOMICS; FEMALE; LEGISLATION AND JURISPRUDENCE; MALE;

CANNABIS; COMMERCE; FEMALE; HUMANS; LEGISLATION, DRUG; MALE; MARIJUANA USE; MEDICAL MARIJUANA; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS;

EID: 85073695474     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31789-1     Document Type: Review

References (103)

1. UNODC. World Drug Report 2018. New York: United Nations, 2018.
2. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564–74.
3. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1345–422.
4. Room R, Fischer B, Hall WD, Lenton S, Reuter P. Cannabis policy: moving beyond stalemate. Oxford: Oxford University Press, 2010.
5. Hall WD. Medical use of cannabis and cannabinoids: questions and answers for policymaking. 2018. http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf (accessed Aug 14, 2019).
6. Caulkins JP. Recognizing and regulating cannabis as a temptation good. Int J Drug Policy 2017; 42: 50–56.
7. Van Keymeulen E. Cannabis legal & regulatory update: October–December 2018. Paris: Allen and Overy, 2019. https://www.jdsupra.com/legalnews/cannabis-legal-regulatory-update-53730/ (accessed Aug 14, 2019).
8. Peacock A, Leung J, Larney S, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 2018; 113: 1905–26.
9. Carvalho AF, Stubbs B, Vancampfort D, et al. Cannabis use and suicide attempts among 86 254 adolescents aged 12–15 years from 21 low- and middle-income countries. European Psychiatry 2018; 56: 8–13.
10. UNODC. World Drug Report 2016. New York: United Nations, 2016.
11. Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE. Demographic subgroup trends among adolescents in the use of various licit and illicit drugs, 1975–2017. 2018. http://www.monitoringthefuture.org/pubs/occpapers/mtf-occ90.pdf (accessed Aug 14, 2019).
12. Compton WM, Han B. The epidemiology of cannabis use in the United States. In: Compton MT, Manseau MW, eds. The complex connection between cannabis and schizophrenia. San Diego: Academic Press, 2018: 9–36.
13. Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 2018; 43: 195–212.
14. Rotermann M, Macdonald R. Analysis of trends in the prevalence of cannabis use in Canada, 1985 to 2015. Health Reports 2018; 29: 10–20.
15. Roxburgh A, Hall WD, Degenhardt L, et al. The epidemiology of cannabis use and cannabis-related harm in Australia 1993–2007. Addiction 2010; 105: 1071–79.
16. EMCDDA. European Drug Report 2017: trends and developments. 2017. http://www.emcdda.europa.eu/publications/edr/trends-developments/2017 (accessed Aug 14, 2019).
17. Bachman J, Wadsworth K, O'Malley P, Johnston L, Schulenberg J. Smoking, drinking, and drug use in young adulthood: the impacts of new freedoms and new responsibilities. Mahwah, NJ: Lawrence Erlbaum, 1997.
18. Terry-McElrath YM, Patrick ME, O'Malley PM, Johnston LD. The end of convergence in developmental patterns of frequent marijuana use from ages 18 to 30: an analysis of cohort change from 1976–2016. Drug Alcohol Depend 2018; 191: 203–09.
19. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci 2019; 269: 5–15.
20. Hall WD, Renström M, Poznyak V. The health and social effects of nonmedical cannabis use. Geneva: World Health Organization, 2016. http://www.who.int/substance_abuse/publications/msb_cannabis_report.pdf (accessed Aug 14, 2019).
21. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press for the National Academies of Sciences Engineering and Medicine, 2017.
22. Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci 2019; 269: 87–105.
23. Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014; 3: e000638.
24. Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid hyperemesis syndrome: reports of fatal cases. J Forensic Sci 2019; 64: 270–74.
25. Beirness D. Drugs and driving: issues and developments. Third International Symposium on Drug-Impaired Driving; Lisbon; Oct 27, 2017.
26. Compton R. Marijuana-impaired driving. A report to Congress. Washington, DC: National Highway Safety Transport Administration, 2017. https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-report-to-congress.pdf (accessed Aug 14, 2019).
27. Kelley-Baker T, Berning A, Ramirez A, et al. 2013–14 National Roadside Study of alcohol and drug use by drivers: drug results. Washington, DC: National Highway Traffic Safety Administration, 2017.
28. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344: e536.
29. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 2016; 111: 1348–59.
30. Krüger H-P, Kazenwadel J, Vollrath M. Grand rapids effects revisited: accidents, alcohol and risk. 1995. http://casr.adelaide.edu.au/t95/paper/s9p2.html (accessed May 16, 2019).
31. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 2016; 6: e009986.
32. Budney AJ, Sofis MJ, Borodovsky JT. An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci 2019; 269: 73–86.
33. Anthony J. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, eds. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press, 2006: 58–105.
34. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharm 1994; 2: 244–68.
35. Coffey C, Patton GC. Cannabis use in adolescence and young adulthood: a review of findings from the Victorian Adolescent Health Cohort Study. Can J Psychiatry 2016; 6: 318–27.
36. Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry 2018; 75: 585–95.
37. Stiby AI, Hickman M, Munafo MR, Heron J, Yip VL, Macleod J. Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction 2015; 110: 658–68.
38. Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend 2010; 110: 247–53.
39. Gage SH, Hickman M, Heron J, et al. Associations of cannabis and cigarette use with depression and anxiety at age 18: findings from the Avon Longitudinal Study of Parents and Children. PLoS One 2015; 10: e0122896.
40. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28.
41. Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord 2016; 195: 63–74.
42. Bhandari S, Jha P, Lisdahl KM, Hillard CJ, Venkatesan T. Recent trends in cyclic vomiting syndrome - associated hospitalizations with liberalization of cannabis use in the state of Colorado. Intern Med J 2018; 49: 649–55.
43. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5: 987–1012.
44. Imtiaz S, Shield KD, Roerecke M, et al. The burden of disease attributable to cannabis use in Canada in 2012. Addiction 2016; 111: 653–62.
45. Rolles S. After the war on drugs: blueprint for regulation. Bristol: Transform Drug Policy Foundation, 2009.
46. Pollack N. I'm just a middle-aged house dad addicted to pot. 2018. https://www.nytimes.com/2018/10/06/opinion/sunday/marijuana-addiction.html (accessed Aug 5, 2019).
47. Conboy JR. Smoke screen: America's drug policy and medical marijuana. Food Drug Law J 2000; 55: 601–17.
48. Leung J, Chiu CYV, Stjepanović D, Hall W. Has the legalisation of medical and recreational cannabis use in the USA affected the prevalence of cannabis use and cannabis use disorders? Current Addiction Reports 2018; 5: 403–17.
49. Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S. Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction 2017; 112: 2206–16.
50. Ries NM. Prescribe with caution: the response of Canada's medical regulatory authorities to the therapeutic use of cannabis. McGill Journal of Law and Health 2016; 9: 215–54.
51. Ablin J, Ste-Marie PA, Schafer M, Hauser W, Fitzcharles MA. Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz 2016; 30: 3–13.
52. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - regulations in Europe and North America. Eur J Intern Med 2018; 49: 2–6.
53. Deutscher Bundestag. Bundestag lässt Cannabis-Arzneimittel für schwerkranke Patienten zu. Berlin: Parliament of the Federal Republic of Germany, 2017. https://www.bundestag.de/dokumente/textarchiv/2017/kw03-de-betaeubungsmittel/487044 (accessed Aug 15, 2019).
54. Gesley J. Germany: Medical Marijuana Act enters into force. 2017. http://www.loc.gov/law/foreign-news/article/germany-medical-marijuana-act-enters-into-force/ (accessed Aug 15, 2019).
55. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456–73.
56. Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018; 159: 1932–54.
57. Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018; 3: CD012182.
58. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018; 89: 741–53.
59. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; 11: CD009464.
60. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry (in press).
61. Higgins J. Cochrane handbook for systematic reviews of interventions. London: Cochrane, 2019.
62. Fairman BJ. Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug Alcohol Depend 2016; 159: 72–79.
63. Hasin DS, Wall M, Keyes KM, et al. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry 2015; 2: 601–08.
64. Sarvet AL, Wall MM, Fink DS, et al. Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. Addiction 2018; 113: 1003–16.
65. Kilmer B, Pacula RL. Building the data infrastructure to evaluate cannabis legalization. Addiction 2017; 112: 1140–41.
66. Hall W, West R, Marsden J, Humphreys K, Neale J, Petry N. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction 2018; 113: 987–88.
67. Kilmer B, MacCoun RJ. How medical marijuana smoothed the transition to marijuana legalization in the United States. Ann Rev Law Soc Sci 2017; 13: 181–202.
68. Felson J, Adamczyk A, Thomas C. How and why have attitudes about cannabis legalization changed so much? Soc Sci Res 2019; 78: 12–27.
69. Garvey T, Yeh BT. State legalization of recreational marijuana: selected legal issues. Washington, DC: Congressional Research Office, 2014. https://fas.org/sgp/crs/misc/R43034.pdf (accessed Aug 15, 2019).
70. McGinty EE, Niederdeppe J, Heley K, Barry CL. Public perceptions of arguments supporting and opposing recreational marijuana legalization. Prev Med 2017; 99: 80–86.
71. Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. Int J Drug Policy 2014; 25: 727–35.
72. Washington State Liquor and Cannabis Board. Marijuana education—know the law. Olympia, WA: State of Washington, 2016. https://lcb.wa.gov/mj-education/know-the-law (accessed Aug 16, 2019).
73. Colorado Department of Public Health and Environment. Marijuana in Colorado. Laws and youth. Denver: State of Colorado, 2019. https://www.colorado.gov/pacific/marijuana/laws-and-youth (accessed May 16, 2019).
74. Subritzky T, Pettigrew S, Lenton S. Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. Int J Drug Policy 2015; 27: 1–12.
75. Cruz JM, Boidi MF, Queirolo R. The status of support for cannabis regulation in Uruguay 4 years after reform: evidence from public opinion surveys. Drug Alcohol Rev 2018; 37: S429–34.
76. Queirolo R, Boidi MF, Cruz JM. Cannabis clubs in Uruguay: the challenges of regulation. Int J Drug Policy 2016; 34: 41–48.
77. Cox C. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. Health Policy 2018; 122: 205–09.
78. Government of Canada. Cannabis Act (S.C. 2018, c. 16). Ottawa, Ontario: Department of Justice, 2018. https://laws-lois.justice.gc.ca/eng/acts/C-24.5/index.html (accessed Sept 30, 2019).
79. Grucza RA, Vuolo M, Krauss MJ, et al. Cannabis decriminalization: a study of recent policy change in five US states. Int J Drug Policy 2018; 59: 67–75.
80. Hudak J, Ramsey G, Walsh J. Uruguay's cannabis law: pioneering a new paradigm. Washington, DC: Center for Effective Public Management at Brookings, 2018.
81. Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 2017; 112: 2167–77.
82. Dilley JA, Richardson SM, Kilmer B, Pacula RL, Segawa MB, Cerda M. Prevalence of cannabis use in youths after legalization in Washington State. JAMA Pediatr 2019; 173: 192–93.
83. Chan GCK, Hall W, Freeman TP, Ferris J, Kelly AB, Winstock A. User characteristics and effect profile of butane hash oil: an extremely high-potency cannabis concentrate. Drug Alcohol Depend 2017; 178: 32–38.
84. Freeman TP, van der Pol P, Kuijpers W, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med 2018; 48: 2346–52.
85. Aydelotte JD, Brown LH, Luftman KM, et al. Crash fatality rates after recreational marijuana legalization in Washington and Colorado. Am J Public Health 2017; 107: 1329–31.
86. Babor T, Caetano R, Casswell S, et al. Alcohol: no ordinary commodity: research and public policy. Oxford: Oxford University Press, 2010.
87. Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? Lancet Psychiatry 2017; 4: 643–48.
88. Caulkins JP, Hawken A, Kilmer B, Kleiman M. Marijuana legalization: what everyone needs to know. New York: Oxford University Press, 2012.
89. Ferri M, Allara E, Bo A, Gasparrini A, Faggiano F. Media campaigns for the prevention of illicit drug use in young people. Cochrane Database Syst Rev 2013; 6: CD009287.
90. Hornik R, Jacobsohn L, Orwin R, Piesse A, Kalton G. Effects of the National Youth Anti-Drug Media Campaign on youths. Am J Public Health 2008; 98: 2229–36.
91. EMCDDA. Drug treatment overview for Netherlands. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2013. http://www.webcitation.org/6S4yjPY59 (accessed Aug 16, 2019).
92. Foxcroft DR, Tsertsvadze A. Universal family-based prevention programs for alcohol misuse in young people. Cochrane Database Syst Rev 2011; 9: CD009308.
93. EMCDDA. Prevention of addictive behaviours. Luxembourg: Publications Office of the European Union, 2015.
94. Foxcroft DR. Can prevention classification be improved by considering the function of prevention? Prev Sci 2014; 15: 818–22.
95. Faggiano F, Vigna-Taglianti FD, Versino E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs' use. Cochrane Database Syst Rev 2005; 2: CD003020.
96. Faggiano F, Minozzi S, Versino E, Buscemi D. Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev 2014; 12: CD003020.
97. Fischer B, Russell C, Sabioni P, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health 2017; 107: e1–12.
98. Quilter J, McNamara L. Zero tolerance drug driving laws in Australia: a gap between rationale and form? Int J Crime Justice Soc Democracy 2017; 6: 47–71.
99. Beirness D, Porath AJ. Cannabis use and driving—an update. Clearing the smoke on cannabis. 2017. https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Cannabis-Use-Driving-Report-2017-en.pdf (accessed Aug 16, 2019).
100. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am 2012; 35: 309–26.
101. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; 12: CD008940.
102. Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS. Cannabinoid replacement therapy (CRT): nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 2015; 97: 571–74.
103. Schroyer J. The great glut: how growers, retailers can adapt when too much cannabis hits the market. 2017. https://mjbizmagazine.com/the-great-glut/ (accessed Aug 16, 2019).